SK Biopharm Targets North American Market... Conducts Nationwide Sales Meeting

The 4th Event Since 2020

[Asia Economy Reporter Myung-Hwan Lee] SK Biopharm announced on the 15th that its U.S. subsidiary, SK Life Sciences, has been holding the '2023 National Sales Meeting' in San Diego, USA, since the 13th.

Lee Dong-hoon, President of SK Biopharm, is giving a presentation at a local sales meeting held in San Diego, USA, on the 13th (local time). Photo by SK Biopharm

This is the fourth time SK Life Sciences has held the National Sales Meeting since 2020. The National Sales Meeting is an event where U.S. pharmaceutical companies encourage their sales organizations and share future visions, and among domestic pharmaceutical companies, only SK Biopharm's local subsidiary holds this event in the United States.

During this sales meeting, SK Biopharm President Dong-Hoon Lee shared the achievements and vision of the epilepsy drug Cenobamate (U.S. brand name Xcopri) with over 160 local employees.

President Lee praised, "The fact that Cenobamate was able to grow more than twice compared to the previous year in the U.S. market last year was possible thanks to the efforts of all employees." He added, "This year, by strengthening sales targeting local medical professionals and patients who have no prior experience with Cenobamate prescriptions, we expect to trigger this potential and achieve a sustainable growth structure."

SK Biopharm is the first and only domestic pharmaceutical company to have a direct sales organization through its U.S. subsidiary and conduct sales activities in the U.S. market. The company plans to accelerate growth further through this National Sales Meeting.

This content was produced with the assistance of AI translation services.